During the second period (M12-M24) and along the whole duration of it (M1-M24) of the project we have sequentially achieved each and every single milestone as stated in the proposal. Following Ethics approval for the different clinical studies over 30 clinical sites were initiated to recruit subjects for the different studies including controls.
Over 5000 samples have been obtained from all of the studies combined, processed and analyzed in what has been the greatest telomere-based clinical study ever conducted.
A machine learning data analysis and validation of the results has rendered prediction models on specific groups of patients from the different studies demonstrating the clinical significance of TAVs. In particular, the application of TAVs as a risk-score based biomarker to save unnecessary biopsies in prostate cancer detection grants the next phase of clinical development of our test for market approval.
A dedicated webpage and brand registration for ONCOCHECK were created as active platforms to disseminate our work. Communication has been reinforced with abstract presented to oncology international meetings, business development at BIO-specific conferences, press releases and webinars as well as social media activities; blogs and tweets that have been constantly updated until month 24.
Most importantly, the work performed in the project and the results have also allowed us to reinforce our IP position with the filling of a European patent application in December 2018.
Life Length has undergone its revalidation as Medical Laboratory (CLIA, ISO15189, A2LA and Spanish Health Ministry) successfully twice during the Oncocheck project; in 2017 and in 2018, which ensures the quality of the clinical development of the TAVs platform into oncology biomarkers.
